Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis.

Epstein-Barr virus (EBV) associated T/NK-cell lymphoproliferative diseases (EBV-T/NK-LPDs) are a cluster of diseases that include chronic active EBV infection (CAEBV) and aggressive NK cell leukemia (ANKL). The pathogenesis of EBV-T/NK-LPDs is largely unclear and the treatment is difficult and in most cases a hematopoietic stem cell transplantation is needed. Hemophagocytic lymphohistiocytosis (HLH) is known to affect the prognosis of patients with EBV-T/NK-LPDs. This study reports a case of a 20-year-old male patient with repeated infectious mononucleosis (IM)-like symptoms such as high fever, splenomegaly, lymphadenopathy for more than two years. The patient had a high EBV-DNA load (NK cells were the main target cells). He was first diagnosed as CAEBV. However, the disease gradually progressed and the patient developed with high ferritin, phagocytosis and monoclonal NK cells in bone marrow, pancytopenia, increased cytokines, and elevated expression of Ki-67. Also, his NK cells had abnormal immunophenotypes and impaired function. The patient had a typical clinical course of progression from CAEBV to ANKL, accompanied by HLH complications and a poor prognosis. Herein, the detailed diagnostic and differential diagnostic process of EBV infection was shown in this report.

[1]  P. Brousset,et al.  Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features , 2021, Cancers.

[2]  J. Xiong,et al.  Inherited Genetic Susceptibility to Nonimmunosuppressed Epstein-Barr Virus-associated T/NK-cell Lymphoproliferative Diseases in Chinese Patients , 2021, Current Medical Science.

[3]  C. Shannon-Lowe,et al.  Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. , 2021, Blood.

[4]  C. Münz Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis , 2020, Cells.

[5]  L. Weiss,et al.  EBV-Associated Lymphoproliferative Disorders: Update in Classification. , 2019, Surgical pathology clinics.

[6]  H. Kimura,et al.  Editorial: Epstein-Barr Virus-Associated T/NK-Cell Lymphoproliferative Diseases , 2019, Front. Pediatr..

[7]  K. Nevel,et al.  Central Nervous System Involvement of Natural Killer and T Cell Neoplasms , 2019, Current Oncology Reports.

[8]  H. Kimura,et al.  Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases , 2019, Front. Pediatr..

[9]  A. Arai Chronic active Epstein–Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements , 2018, Immunological medicine.

[10]  L. Weiss,et al.  Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update. , 2018, Human pathology.

[11]  T. Koyama,et al.  STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target , 2018, Oncotarget.

[12]  W. Chan,et al.  Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target , 2018, Nature Communications.

[13]  J. Cohen,et al.  Chronic Active Epstein–Barr Virus Disease , 2017, Front. Immunol..

[14]  Shaoping Ling,et al.  Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes , 2017, Blood Cancer Journal.

[15]  Sonali M. Smith,et al.  Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  P. Khong,et al.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.

[17]  K. Kawa,et al.  How we treat chronic active Epstein–Barr virus infection , 2017, International Journal of Hematology.

[18]  T. Murata,et al.  Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells , 2016, Oncotarget.

[19]  Y. Ko,et al.  l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia , 2016, Journal of Hematology & Oncology.

[20]  L. Huebsch,et al.  A relapsed aggressive NK‐cell leukemia with CNS involvement diagnosed by cerebrospinal fluid examination , 2016, Diagnostic cytopathology.

[21]  M. Du,et al.  Aggressive natural killer-cell neoplasm presenting in the marrow: a report of two cases including one with gains of chromosomes 4q and 9p , 2015, Diagnostic Pathology.

[22]  A. Fischer,et al.  LYST Controls the Biogenesis of the Endosomal Compartment Required for Secretory Lysosome Function , 2015, Traffic.

[23]  Liang-ding Hu,et al.  Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. , 2014, Blood.

[24]  Danmei Xu,et al.  Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. , 2014, Translational research : the journal of laboratory and clinical medicine.

[25]  T. Murata,et al.  Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein–Barr virus-associated T cell and natural killer cell lymphoma , 2014, Cancer science.

[26]  J. Ouyang,et al.  Six cases of aggressive natural killer-cell leukemia in a Chinese population. , 2014, International journal of clinical and experimental pathology.

[27]  Y. Kwong,et al.  How I treat NK/T-cell lymphomas. , 2013, Blood.

[28]  R. Suzuki,et al.  Aggressive natural killer cell leukemia: Therapeutic potential of l‐asparaginase and allogeneic hematopoietic stem cell transplantation , 2012, Cancer science.

[29]  Takashi Saito,et al.  Antitumor activities of valproic acid on Epstein–Barr virus‐associated T and natural killer lymphoma cells , 2012, Cancer science.

[30]  N. Jiang,et al.  Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood , 2012, Annals of Hematology.

[31]  K. Sugimoto,et al.  Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein‐Barr virus infection , 2011, International journal of cancer.

[32]  K. Kawa,et al.  Clinicopathological analysis of the age‐related differences in patients with Epstein–Barr virus (EBV)‐associated extranasal natural killer (NK)/T‐cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection‐associated lymphoproliferative disorde , 2011, Histopathology.

[33]  Hee-Jin Kim,et al.  Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker. , 2009, The Korean journal of laboratory medicine.

[34]  E. Jaffe,et al.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Y. Ko,et al.  Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis? , 2009, Acta Haematologica.

[36]  K. Ohshima,et al.  Proposed categorization of pathological states of EBV‐associated T/natural killer‐cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T‐LPD , 2008, Pathology international.

[37]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[38]  R. Irons,et al.  Aggressive Natural Killer Cell Leukemia: Report of a Chinese Series and Review of the Literature , 2007, International journal of hematology.

[39]  Y. Nakazawa,et al.  Significance of chemokine receptor expression in aggressive NK cell leukemia , 2005, Leukemia.

[40]  D. Catovsky,et al.  Prolonged treatment response in aggressive natural killer cell leukemia , 2005, Leukemia & lymphoma.

[41]  K. Kawa,et al.  Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells , 2004, Leukemia.

[42]  R. Egeler,et al.  HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.